Abstract: A dry hydrated cephalosporin, e.g. ceftibuten having about 7 to 14% by weight of water, powder formulation, pharmaceutical compositions in the form of an oral suspension dosage form and a method of making the dry powder formulations are disclosed.

Abstract: A compound represented by formula I, Ar.sub.1 --O--M--O--Ar.sub.2, wherein Ar.sub.1 and Ar.sub.2 are independently substituted phenyl or substituted pyridinyl, the substituents on said phenyl or pyridinyl being independently selected from one, two or three of (C.sub.1 -C.sub.10) alkyl, (C.sub.1 -C.sub.10) alkoxy, halogen, carbamyl, (C.sub.1 -C.sub.10) alkoxycarbonyl, oxazoyl, and (C.sub.1 -C.sub.10) alkyl substituted by halogen, (C.sub.1 -C.sub.10) alkoxy, hydroxy, or (C.sub.1 -C.sub.10) alkoxycarbonyl; ##STR1## O is oxygen; R' is (C.sub.1 -C.sub.3 alkyl or H; A is oxygen or sulfur; Q is selected from hydrogen, halogen, nitro, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 C.sub.6) perhaloalkyl, (C.sub.1 -C.sub.6) alkylthio (C.sub.1 -C.sub.

Abstract: An applicator 10 includes a barrel 12 for containing a semisolid medicinal, the barrel including a large diameter cylindrical section 16, a small diameter cylindrical section 18 and an annular sloped transition section 20 that connects the large diameter cylindrical section and the small diameter cylindrical section, the sections being coaxial with each other, the small diameter cylindrical section including an inner surface defining an internal cavity for containing the medicinal, a first end 30 with a first opening 32 and equiangularly spaced, axially aligned evacuation channels 28 in the inner surface for venting air out of the barrel when the internal cavity is filled with the medicinal, and the large diameter cylindrical section includes a second opposite end with a second opening 24; a rubber plunger 58 for pushing the medicinal through the first opening, the plunger being slidably positioned in sealing contact with the inner surface of the small diameter cylindrical section; a plunger rod 86 connected

Abstract: Aerosol formulations substantially free of chlorofluorocarbons for oral and/or nasal administration are described. The formulations comprise 1,1,1,2,3,3,3-heptafluoropropane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations are also described.

Abstract: A method of treating mammals infected with HIV-1, or AIDS by administering a therapeutically effective amount of a compound represented by formula I ##STR1## or a pharmaceutically acceptable salt or ester thereof or stereoisomer thereof and pharmaceutical compositions containing it are disclosed.

Abstract: A compound represented by formula IAr.sub.1 --O--M--O--AR.sub.2 Iwherein Ar.sub.1 and Ar.sub.2 are independently substituted phenyl or substituted pyridinyl, the substituents on said phenyl or pyridinyl being independently selected from one, two or three of (C.sub.1 -C.sub.10)alkyl, (C.sub.1 -C.sub.10) alkoxy, halogen, carbamyl, (C.sub.1 -C.sub.10) alkoxycarbonyl, oxazoyl, and (C.sub.1 -C.sub.10) alkyl substituted by halogen, (C.sub.1 -C.sub.10) alkoxy, hydroxy, or (C.sub.1 -C.sub.10) alkoxycarbonyl; ##STR1## M is (C.sub.4 -C.sub.8) alkylene, (C.sub.4 -C.sub.8) alkenylene or(C.sub.4 -C.sub.8)-alkynylene;O is oxygen;or pharmaceutically acceptable salts thereof.as well as pharmaceutical compositions containing the compounds and methods of treating or preventing viral infections, especially picornaviral infections, are disclosed.

Abstract: Non-aqueous sunscreen compositions containing an amount of a volatile silicone oil sufficient to maintain the SPF of the waterproof composition at a value greater than about 20 and a conventional non-aqueous sunscreen formulation or a conventional non-aqueous waterproof sunscreen formulation.

Abstract: A cosmetically elegant, physically and chemically stable base in the form of an oil-in-water emulsion for use in cream and lotion lipophilic drug containing- pharmaceutical compositions containing at least one lipophilic drug and an effective amount of N-methyl-2-pyrrolidone is disclosed.

Abstract: Two novel glycosides of 3'-deoxyaquayamycin isolated from an antimicrobial complex produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces sp. SCC 2136, ATCC 55186 are disclosed.

Abstract: A method of using IL-4, the use of IL-4 for the manufacture of a medicament and pharmaceutical compositions containing IL-4, for treating solid tumor growth by systemically injecting IL-4, such as hIL-4 or recombinant E. coli--derived IL-4, into mammals afflicted with solid tumors is disclosed.

Abstract: Novel macrocyclic lactone antibacterials isolated from a culture containing the microorganism S. aerocolongenes sub sp. antibiotica SCC 1886, ATTC 55003 and their use for treating and/or preventing antibacterial infections, especially Chlamydia infections are disclosed.

Abstract: A compound represented by formula IAr.sub.1 --O--M--O--Ar.sub.2 Iwherein Ar.sub.1 and Ar.sub.2 are independently substituted phenyl or substituted pyridinyl, the substituents on said phenyl or pyridinyl being independently selected from one, two or three of (C.sub.1 -C.sub.10) alkyl, (C.sub.1 -C.sub.10) alkoxy, halogen, carbamyl, (C.sub.1 -C.sub.10) alkoxycarbonyl, oxazoyl, and (C.sub.1 -C.sub.10) alkyl substituted by halogen, (C.sub.1 -C.sub.10) alkoxy, hydroxy, or (C.sub.1 -C.sub.10) alkoxycarbonyl; M is ##STR1## (C.sub.4 -C.sub.8) alkylene, (C.sub.4 -C.sub.8) alkenylene or (C.sub.4 -C.sub.8)-alkynylene;O is oxygen;or pharmaceutically acceptable salts thereof.as well as pharmaceutical compositions containing the compounds and methods of treating or preventing viral infections, especially picornaviral infections, are disclosed.

Abstract: Novel macrocyclic lactone antibacterials isolated from a culture containing the microorganism S. aerocolongenes sub sp. antibiotica SCC 1886, ATTC 55003 and their use for treating and/or preventing antibacterial infections, especially Chlamydia infections are disclosed.

Abstract: Four bicyclic terpenes isolated from a culture broth of Phoma sp SCF0592, ATCC 74077, pharmaceutical compositions containing them and their use as PAF antagonists to treat allergic and inflammatory diseases are disclosed.

Abstract: A film-coated extended release oral dosage composition containing the nasal decongestant pseudoephedrine sulfate in a unique polymer matrix core and a film-coating on such core containing the non-sedating antihistamine, loratadine, and use of the said composition for treating patients showing the signs and symptoms associated with upper respiratory diseases and nasal congestion are disclosed.

Abstract: Human leukemia T-cells and B-cells are inhibited from proliferating by treatment with a combination of recombinant human alpha and gamma interferons, either simultaneously or sequentially, and the alpha interferon is preferably recombinant human alfa-2b interferon.

Abstract: Stable sustained release wax- and polymer-coated drug-ion exchange resin complexes especially useful in preparing oral suspensions are disclosed.

Abstract: The novel triacetylenic dioxolone antifungal compound of this invention is isolated from the EV-22 complex of this invention which is elaborated by the microorganism Microbispora sp. SCC 1438, ATCC 53620.

Abstract: A compound represented by the formula I: ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen or (C.sub.2 -C.sub.10) alkanoyl in substantially chemically pure form, and pharmaceutical compositions thereof are disclosed.

Abstract: An aqueous, flavored, topical, nasal decongestant composition containing an amount of oxymetazoline or a pharmaceutically acceptable salt thereof e.g., oxymetazoline HCl sufficient to effect nasal decongestion and an amount of a fruity flavor e.g. cherry flavor, sufficient to mask the medicinal after-taste of the composition, together with an aqueous carrier.